BackBristol-Myers Squibb Company Overview

Bristol-Myers Squibb Company EBIT

Bristol-Myers Squibb Company's EBIT is $14B, below the Healthcare sector average of $1.9T.

Get informed when a big investor buys or sells

+ Follow

Quarterly EBIT

$4.51B
↑ 44.93% YoY

As of Sep 30, 2026

Annual EBIT (TTM)

$13.64B
↑ 88.19% YoY

Trailing 12 months ending Sep 30, 2026

Average EBIT (Comparison Companies)

EBIT History

EBIT Comparison

Annual EBIT Growth Rate (%)

Annual EBIT Growth (Absolute)

Bristol-Myers Squibb Company (BMY.SW) FAQ

As of the most recent data (September 2026), BMY.SW shows a EBIT of $14B. That compares with $7.2B in the prior-year period — up 88.2% year over year. That is below the Healthcare sector average of $1.9T. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, BMY.SW's EBIT is now $14B (was $7.2B) — a 88.2% year-over-year increase. Pairing that YoY change with peer averages gives a clearer picture of whether Bristol-Myers Squibb Company is outperforming or lagging.

The Healthcare sector average EBIT is about $1.9T. Bristol-Myers Squibb Company is at $14B, which is lower that average. That is roughly 99.3% below the sector mean. Use the comparison chart on this page to see how BMY.SW stacks up against individual peers as well.

Tracking BMY.SW's ebit over time shows whether Bristol-Myers Squibb Company is scaling, shrinking, or reshaping that part of the business. The current reading is $14B That compares with $7.2B in the prior-year period — up 88.2% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this ebit page, Stockcircle has Bristol-Myers Squibb Company's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect EBIT (currently $14B) with ownership activity and broader fundamentals.

Questions & Answers